Dare Bioscience Inc (DARE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dare Bioscience Inc (DARE) has a cash flow conversion efficiency ratio of 0.508x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.44 Million) by net assets ($2.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Dare Bioscience Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Dare Bioscience Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Dare Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Dare Bioscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dare Bioscience Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Touch Ventures Ltd
AU:TVL
|
0.006x |
|
PowerBank Corporation
NASDAQ:SUUN
|
0.100x |
|
Medical Developments International Ltd
AU:MVP
|
0.013x |
|
iCRAFT Co. Ltd
KQ:052460
|
0.170x |
|
P-Two Industries
TWO:6158
|
0.098x |
|
Shaftesbury Capital PLC
LSE:SHC
|
0.010x |
|
Trisula International Tbk
JK:TRIS
|
0.121x |
|
Agroton Public Ltd.
WAR:AGT
|
-0.142x |
Annual Cash Flow Conversion Efficiency for Dare Bioscience Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Dare Bioscience Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Dare Bioscience Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.84 Million | $-9.89 Billion | -3477.715x | -387504.24% |
| 2024-12-31 | $-6.01 Million | $5.39 Million | -0.897x | -111.66% |
| 2023-12-31 | $-5.05 Million | $-38.86 Million | 7.698x | +572.90% |
| 2022-12-31 | $11.11 Million | $-18.09 Million | -1.628x | -119.32% |
| 2021-12-31 | $38.75 Million | $-28.76 Million | -0.742x | -103.39% |
| 2020-12-31 | $-1.15 Million | $-25.23 Million | 21.910x | +172.54% |
| 2019-12-31 | $440.83K | $-13.32 Million | -30.206x | -1878.71% |
| 2018-12-31 | $6.73 Million | $-10.27 Million | -1.527x | -698.85% |
| 2017-12-31 | $13.29 Million | $-2.54 Million | -0.191x | +92.53% |
| 2016-12-31 | $13.11 Million | $-33.54 Million | -2.558x | -290.65% |
| 2015-12-31 | $48.74 Million | $-31.91 Million | -0.655x | -55.70% |
| 2014-12-31 | $45.33 Million | $-19.06 Million | -0.421x | -107.06% |
| 2013-12-31 | $-2.79 Million | $-16.61 Million | 5.959x | +2170.70% |
| 2012-12-31 | $-80.04 Million | $-21.00 Million | 0.262x | +119.21% |
| 2011-12-31 | $12.35 Million | $-16.88 Million | -1.366x | -- |
About Dare Bioscience Inc
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of… Read more